scholarly journals Correlations of Expression Levels of a Panel of Genes (IRF5, STAT4, TNFSF4, MECP2, and TLR7) and Cytokine Levels (IL-2, IL-6, IL-10, IL-12, IFN-γ, and TNF-α) with Systemic Lupus Erythematosus Outcomes in Jordanian Patients

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Amal H. Uzrail ◽  
Areej M. Assaf ◽  
Shtaywy S. Abdalla

Systemic lupus erythematosus (SLE) is characterized by systemic end-organ damage. We investigated the involvement of IRF5, TLR-7, MECP2, STAT4, and TNFSF4 genes and TNF-α, IFN-γ, IL-2, IL-12, IL-6, and IL-10 cytokines in SLE pathogenesis and in organ damage in Jordanian patients. Blood was collected from 51 patients and 50 controls. Expression levels of SLE genes in PBMCs and cytokine levels were determined using RT-PCR and ELISA, respectively. Expression levels of all genes and levels of TNF-α, IL-12, IL-6, and IL-10 were higher in SLE patients than those in controls (p<0.05), whereas IL-2 level was lower. High STAT4 (α), TNFSF4, and IL-10 levels correlated with cardiovascular damage, and high MECP2 (α) and TNF-α correlated with renal damage. Pulmonary and musculoskeletal damages correlated with high levels of TNFSF4. We concluded that STAT4 and TNFSF4 genes with TNF-α and IL-10 cytokines could be used as biomarkers to assess SLE activity and manage treatment.

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Hooi-Ming Lee ◽  
Hidehiko Sugino ◽  
Norihiro Nishimoto

Systemic lupus erythematosus (SLE) is an autoimmune disease more prominent in women and characterized by multiple organ damage. Imbalance in cytokine production and cytokine levels correlates with SLE progression, making the understanding of SLE cytokine networks very important for SLE treatment strategy and drug development. In this article, we review cytokine networks that may be involved in the pathogenesis of SLE by briefly describing abnormal cytokine production and serum cytokine levels in SLE patients. We also focus on the pathological roles of cytokines and their interactions in immunoregulatory networks and suggest how their disturbances may implicate in pathological conditions in SLE. Finally, we further discuss the influence of estrogen on these cytokine networks.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1045-1046
Author(s):  
M. Feng ◽  
X. C. Zhao ◽  
J. Luo

Background:Systemic lupus erythematosus (SLE) is a multisystemic inflammatory disorder [1]. Given that immunosuppressive therapy is adopted as the predominant treatment option for SLE, up to half of SLE patients develop infections during their disease progress, and bacterial infection serves as the leading cause of morbidity and mortality in SLE patients [2]. Owing to the therapeutic regimen to bacterial infection and SLE flare are absolutely opposite, timely diagnosis and correct treatment are of vital importance, and improper treatment strategy may be fatal. No single biomarker, however, has exhibited sufficient sensitivity and specificity to serve as a standard tool for distinguishing bacterial infection from SLE flare.Objectives:To find a method by integrating cytokines, lymphocyte cells and routine examination biomarkers to observe its capacity for identifying bacterially infected SLE patients.Methods:Total 175 SLE patients (65 infected and 110 flare) were recruited into our study. The criteria of bacterial infection was positive isolation of bacteria, typical clinical symptoms and signs, imaging positive results and positive feedback on antibacterial treatment and lupus flare was regarded as three points higher than their previous SLEDAI. The disease activity of SLE patients was evaluated based on Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Lymphocyte cells (CD3+T, CD4+T, CD8+T, B, NK, Th1, Th2, Th17 and Treg) and cytokines [interleukin-2 (IL-2), IL-4, IL-6, IL-10, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and IL-17] were measured by flow cytometry. Blood routine examination, erythrocyte sedimentation rate (ESR), C-Reactive Protein (CRP) Complement 3 (C3), C4, procalcitonin (PCT), immunoglobulin M (IgM), IgA and IgG were also evaluated. Partial least square discriminant analysis (PLS-DA) and supervised orthogonal PLS-DA (OPLS-DA) were applied to perform multivariate analysis of the data and further group the patients with bacterial infection. Receiver operating characteristic (ROC) curves were also plotted to investigate the ability of individual indicator and the combination of multiple indicators to identify bacterial infection.Results:The PLS-DA model showed a clear identification effect by the performance of R2Y=0.991 and Q2=0.970. The OPLS-DA model (R2Y=0.996 and Q2=0.991) exhibited a better separation of patients with bacterial infection. And the Observed vs. predicted plot of the OPLS-DA model demonstrated that all SLE patients were correctly separated into infected or flare groups, indicating that the model had a strong predictive ability for bacterial infection. For single indicator, infected patients had higher WBC, neutrophil (NEUT), ESR, CRP and PCT (P=0.002, 0.019, 0.002, <0.001, <0.001, respectively), and lower Treg cells (P=0.012). The levels of serum IL-6, IL-10, IFN-γ and TNF-α (P<0.001, =0.022, 0.014, 0.011, respectively) were significantly increased in infected group. ROC curves showed that the combination of the ten indicators showed the largest AUC and the highest accuracy, as well as balanced and relatively high sensitivity and specificity. Furthermore, the AUC of the combination was greatly higher than that of WBC, NEUT, ESR, CRP, PCT, Treg, IL-6, IL-10, IFN-γ and TNF-α (P<0.001).Conclusion:PLS-DA, OPLS-DA models including cytokines, lymphocyte cells and routine biomarkers and combination of WBC, NEUT, ESR, CRP, PCT, Treg, IL-6, IL-10, IFN-γ and TNF-α in ROC curve may be more predictive for finding bacterial infection in SLE and may prompt clinicians more promptly and accurately to help them make correct medication.References:[1]Illescas-Montes R, Corona-Castro CC, Melguizo-Rodríguez L, et al. Infectious processes and systemic lupus erythematosus. Immunology 2019;158:153-160.[2]Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2002; 61: ii2–7.Disclosure of Interests:None declared


Lupus ◽  
2012 ◽  
Vol 21 (10) ◽  
pp. 1105-1112 ◽  
Author(s):  
A Rana ◽  
RW Minz ◽  
R Aggarwal ◽  
S Anand ◽  
N Pasricha ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Ghulam Mustafa ◽  
Hafiza Salaha Mahrosh ◽  
Mahwish Salman ◽  
Sumaira Sharif ◽  
Raheela Jabeen ◽  
...  

Autoimmune disorder is a chronic immune imbalance which is developed through a series of pathways. The defect in B cells, T cells, and lack of self-tolerance has been greatly associated with the onset of many types of autoimmune complications including rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy. The SLE is an autoimmune disease with a common type of lupus that causes tissue and organ damage due to the wide spread of inflammation. In the current study, twenty anti-inflammatory peptides derived from plant and animal sources were docked as ligands or peptides counter to proinflammatory cytokines. Interferon gamma (IFN-γ), interleukin 3 (IL-3), and tumor necrosis factor alpha (TNF-α) were targeted in this study as these are involved in the pathogenesis of SLE in many clinical studies. Two docking approaches (i.e., protein-ligand docking and peptide-protein docking) were employed in this study using Molecular Operating Environment (MOE) software and HADDOCK web server, respectively. Amongst docked twenty peptides, the peptide DEDTQAMMPFR with S -score of -11.3018 and HADDOCK score of − 10.3 ± 2.5  kcal/mol showed the best binding interactions and energy validation with active amino acids of IFN-γ protein in both docking approaches. Depending upon these results, this peptide could be used as a potential drug candidate to target IFN-γ, IL-3, and TNF-α proteins to control inflammatory events. Other peptides (i.e., QEPQESQQ and FRDEHKK) also revealed good binding affinity with IFN-γ with S -scores of -10.98 and -10.55, respectively. Similarly, the peptides KHDRGDEF, FRDEHKK, and QEPQESQQ showed best binding interactions with IL-3 with S -scores of -8.81, -8.64, and -8.17, respectively.


Lupus ◽  
2019 ◽  
Vol 28 (14) ◽  
pp. 1669-1677 ◽  
Author(s):  
R Kandane-Rathnayake ◽  
J R Kent ◽  
W Louthrenoo ◽  
S -F Luo ◽  
Y -JJ Wu ◽  
...  

Objective To examine longitudinal associations of active lupus nephritis with organ damage accrual in patients with systemic lupus erythematosus (SLE). Methods This study was performed using data from a large multinational prospective cohort. Active lupus nephritis at any visit was defined by the presence of urinary casts, proteinuria, haematuria or pyuria, as indicated by the cut-offs in the SLE Disease Activity Index (SLEDAI)-2K, collected at each visit. Organ damage accrual was defined as a change of SLICC-ACR Damage Index (SDI) score >0 units between baseline and final annual visits. Renal damage accrual was defined if there was new damage recorded in renal SDI domains (estimated glomerular filtration rate <50%/proteinuria >3.5 g per 24 h/end-stage kidney disease). Time-dependent hazard regression analyses were used to examine the associations between active lupus nephritis and damage accrual. Results Patients ( N = 1735) were studied during 12,717 visits for a median (inter-quartile range) follow-up period of 795 (532, 1087) days. Forty per cent of patients had evidence of active lupus nephritis at least once during the study period, and active lupus nephritis was observed in 3030 (24%) visits. Forty-eight per cent of patients had organ damage at baseline and 14% accrued organ damage. Patients with active lupus nephritis were 52% more likely to accrue any organ damage compared with those without active lupus nephritis (adjusted hazard ratio = 1.52 (95% confidence interval (CI): 1.16, 1.97), p < 0.02). Active lupus nephritis was strongly associated with damage accrual in renal but not in non-renal organ domains (hazard ratios = 13.0 (95% CI: 6.58, 25.5) p < 0.001 and 0.96 (95% CI: 0.69, 1.32) p = 0.8, respectively). There was no effect of ethnicity on renal damage accrual, but Asian ethnicity was significantly associated with reduced non-renal damage accrual. Conclusion Active lupus nephritis measured using the SLEDAI-2K domain cut-offs is associated with renal, but not non-renal, damage accrual in SLE.


2018 ◽  
Vol 59 (3) ◽  
pp. 1-16 ◽  
Author(s):  
Julián Esteban Barahona Correa ◽  
Manuel Antonio Franco Cortés ◽  
Juana Ángel Uribe ◽  
Luz Stella Rodríguez Camacho

Introduction: Coexistence of more than one autoimmune disease (AD) in a single patient is known as polyautoimmunity, and may be seen in up to 35% of patients with ADs. The elimination of B-cells using Rituximab (RTX) improves clinical status in different ADs. The role of cytokine production by B-cells is unclear in systemic lupus erythematosus (SLE) and polyautoimmunity. Methods: As an exploratory study, plasma from 11 patients with either rheumatoid arthritis (RA) or SLE-associated polyautoimmunity was assessed prior and 6 months after therapy with RTX. Eight healthy individuals were used as controls. Cytokine levels were measured using ELISA (IFN-α and TGF-β1) or Cytometric Bead Array (TNF-α, IL-1β, IL-6, IL-8, IL-10, and IL-12p70). Results: Prior to RTX, IL-6 was only elevated in RA and IL-8 was elevated in both RA and SLE-associated polyautoimmunity, compared with controls. After RTX, significant decreases of IL-6 in RA and IL-8 in SLE-associated polyautoimmunity were observed. Levels of other cytokines measured were either similar (IFN-α, TGF β1) or below the detection limit (TNF-α, IL-1β, IL-10, IL-12p70) for both patients and controls. Conclusion:Our data highlight the importance of B-cell cytokine secretion in RA and SLE-associated polyautoimmunity, and suggest a differential role in each pathology. A significant increase of IL-8 prior to RTX in both groups, and a significant decrease after therapy only in SLE-associated polyautoimmunity support the potential of IL-8 as a therapeutic target. The heterogeneity of the polyautoimmunity patient population highlights the importance of the selection of specific subsets in future research.


Clinics ◽  
2011 ◽  
Vol 66 (1) ◽  
pp. 77-82 ◽  
Author(s):  
José Ronaldo M Carneiro ◽  
Hellen T Fuzii ◽  
Cristiane Kayser ◽  
Fernando L Alberto ◽  
Fernando A Soares ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Zhuang Ye ◽  
Yanfang Jiang ◽  
Dejun Sun ◽  
Wei Zhong ◽  
Ling Zhao ◽  
...  

Abstract Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that is associated with the destruction of immune tolerance and activation of B cells. Interleukin (IL)-35 and IL-35-producing (IL-35+) regulatory B cells (Bregs) have been demonstrated to possess immunosuppressive functions, but their roles in the initiation and early development of SLE have not been explored. Here, we measured and compared the frequencies of blood regulatory B cell subsets and the concentrations of plasma IL-35, IL-10, IL-17A, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ in 47 Chinese patients with newly diagnosed SLE and 20 matched healthy controls (HCs). The SLE patients had decreased percentages of IL-35+ B cells and IL-10+ B cells among the total blood B cells as well as decreased concentrations of plasma IL-35. In addition, higher levels of plasma IL-10, IFN-γ, TNF-α, and IL-17 along with higher frequencies of circulating plasma and memory B cells were observed in the SLE patients. The percentage of IL-35+ Bregs and the serum IL-35 level were inversely correlated with the SLE disease activity index and the erythrocyte sedimentation rate (ESR) levels. Our results indicate that IL-35+ Bregs and IL-35 may play protective roles in SLE initiation and progression.


Sign in / Sign up

Export Citation Format

Share Document